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Conclusion: There is evidence to suggest a dose volume 
effect between the PB and EP. Discriminatory PB dose-
volume constraints were found to predict G2 EP. Further 
analysis is in progress to include patient reported outcomes 
related to EP.  
Ref: (1) Wallner, IJROBP 2002 (2) Perna, Rad Onc 2011 (3) 
Gay, IJROBP 2012 
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Purpose or Objective: Radiation-induced rectal incontinence 
has a negative impact on Quality of Life in patients irradiated 
for prostate cancer. Several studies identified dose-effect 
relationships for the anal canal and lower rectum and hence, 
dose constraints for treatment planning have been 
implemented. We studied patient-reported rectal 
incontinence in a population treated with Image-guided 
intensity modulated radiotherapy (IG-IMRT) and planned with 
a dose constraint for the anal canal, and compared it with a 
reference population treated with 3D-conformal radiotherapy 
(3D-CRT) with no dose constraint for the anal canal. For that 
purpose we analyzed data from two large prospective cohorts 
 
Material and Methods: We selected patients treated to 78Gy 
(39x2Gy) from two trials (CKTO 96-10 and CKTO 2006-08), 
who completed at least 2 follow-up questionnaires which 
included questions on pad use and fecal incontinence (IGIMRT 
group n=242, 3DCRT group n=189). In the IG-IMRT group, 
mean dose to the anal canal was restricted to 58 Gy per 
protocol (more strict constraints depended on local planning 
guidelines). Grade ≥2 (G≥2) incontinence was defined as use 
of pads for uncontrolled loss of feces or mucus, Grade ≥1 
(G≥1) incontinence was defined as any reported fecal 
incontinence regardless use of pads. Prevalence and 
cumulative incidences of G≥2 and G≥1 incontinence were 
calculated. Cox regression was used to calculate Relative 
Risks (RR) 
 
Results: Planned mean dose to the anal canal was on average 
44.6 Gy (range 17-65) for 3D-CRT and 23.6 Gy (range 3-50) 
for IG-IMRT (p<0.001). Median follow-up was 60 months. The 
5y cumulative incidence of G≥2 incontinence was 15.2% for 
IG-IMRT vs 14.9% for 3D-CRT (RR=1.02, p=0.9). Prevalence of 
G≥1 incontinence was ≈ 5% at baseline and in the range of 
30% - 40% in the years after treatment, with no significant 
differences between the groups (Figure 1). Within the 3D-CRT 
group, previous abdominal surgery was predictive for G≥2 
incontinence (RR=2.1, p=0.05), whereas age >70 years at 
start RT (RR=2.9, p<0.01), diabetes mellitus (RR=2.4, 
p=0.04), and seminal vesicle dose ≥70 Gy vs 0 Gy (RR=9.2, 
p=0.03) were predictive in the IG-IMRT group. At multivariate 
analysis, adjusting for the significant baseline factors, RR of 
mean anal canal dose was 1.00 (p=0.9) for IG-IMRT patients 
and 1.05 (for each increase of 1 Gy) for 3D-CRT (p=0.04). 
Acute toxicity G≥2 (mainly proctitis) was predictive (p<0.01) 
in both groups with a RR of 3.1 (IG-IMRT) and 4.1 (3D-CRT). 
G≥1 incontinence at any time during follow-up was 
significantly associated with abdominal surgery in the 3D-CRT 
group, and with age >70 years, and diabetes mellitus in the 
IG-IMRT group 
 
Conclusion: IG-IMRT with anal canal dose constraints did not 
reduce long-term incidence of rectal incontinence in prostate 
cancer patients, despite significantly reduced dose levels to 
the anal canal region. Further investigations are needed to 
understand the mechanisms of radiation damage causing 
rectal incontinence 
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Purpose or Objective: To assess the toxicity and feasibility 
of concomitant radiotherapy with low doses of docetaxel plus 
standard hormonal treatment in patients with high risk 
localized prostate cancer. 
 
Material and Methods: Patients were randomly assigned to 
either arm A (LH-RH analogs every 3 months for 3 years and 
radiotherapy 74 Gy [2Gy x 37 fractions]) or arm B (LH-RH 
analogs every 3 months for 3 years, radiotherapy 73.8 Gy [1.8 
Gy x 41 fractions] and concurrent weekly docetaxel at 20 
mg/m2 for 9 weeks). Chemotherapy was started one week 
before of radiotherapy. Primary endpoint was PSA relapse 
according to the Phoenix definition. The planned number of 
patients was 130 to detect a 15% difference with a power of 
80% and an alpha of 0.05 (two-sided).  
 
Results: From 12/2008 to 9/2012, 130 pts were accrued (Arm 
A: 64, Arm B: 66). Median age was 68 years (61-73). Patients 
had T3-T4 (82.6%), Gleason Score ≥ 8 (76.3%), PSA > 20 
ng/mL (26.9%) and pN+ (18.9%). All characteristics were well-
balanced between arms. Median dose of radiotherapy was 74 
Gy (72–74.8) in arm A, and 73.8 Gy ( 72-75.6) in arm B. 75.7% 
of patients received the planned 9 treatments of docetaxel 
and median number of cycles delivered per patient was 9. 
After a median follow-up of 29.6 months (9.6-40.2), most 
common grade 1/2 toxicities (arm A and arm B) were: cystitis 
( 12.5% vs 8.3%), diarrhea (35.9% vs 70%), proctitis (12.5% vs 
13.3%), rectal tenesmus (3.1% vs 23.3%), asthenia (23.4% vs 
61.6%) and dysuria ( 28.1% vs 30.0%). Toxicity grade3/4, 
diarrhea was reported in 8.3% of patients in arm B and 0% in 
arm A. Grade3/4 lymphopenia occurred less often in arm A 
than in arm B (3.1% vs 23.3%). %). There was no toxicity-
related death.  
 
Conclusion: The QRT SOGUG phase IIb trial shows that 
standard doses of radiotherapy and concurrent weekly 
docetaxel can be administered without increasing toxicity 
profile.  
 
 
 
 
 
 
